Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to approach the situation.
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT)
fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price target by nearly 50% to $87. The downgrade was driven by weaker-than-anticipated feedback from physicians regarding ELEVIDYS, suggesting that market reception for the treatment had fallen short. Notably, ELEVIDYS had been a big piece of Sarepta's growth story as it contributed more than 50% of sales in the Q4'2024 quarter.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.
U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31
